Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D3S-003 in Advanced Solid Tumors With a KRAS p.G12D Mutation
NCT07456046Phase 1Recruiting
- Sponsor
- D3 Bio
- Start
- May 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of D3S-003 in solid tumor, sponsored by D3 Bio. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events and 2 more. Started May 2026; status: recruiting.
02
Drugs
D3S-003
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07456046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07456046.